The authors proposed a novel classification that links molecular profile of meningiomas with their potential to recur: (1) benign tumors that carry intact NF2, but have mutations in other genes (e.g., TRAF7, AKT1, KLF4); (2) benign tumors that carry biallelic loss of NF2 and presented with SWI/SNF and PRC2 gene involvement; and (3) aggressive meningiomas with high risk of recurrence that have inactivated NF2 and carry chromosome 1p loss and the loss of the repressor function of DREAM, a chromatin-remodeling complex involved in cell cycle progression38. The gene discussed is SMARCA1; the disease is benign neoplasm.